Key Highlights

● Liam Kelly will become Nyxoah's Chief Executive Officer effective October 1, 2026, succeeding Olivier Taelman, according to a Form 6-K.

● Mr. Kelly was Chairman, President and Chief Executive Officer of Teleflex until January 2026 and joined that company in 2009.

● Nyxoah's lead product, the Genio system, received the European CE Mark in 2019 and FDA approval in August 2025.

● Chairman Robert Taub said Nyxoah is entering a new chapter, with the United States central to its growth strategy.

Nyxoah SA (NASDAQ:NYXH), the Belgian medical technology company whose shares trade on Nasdaq under the symbol NYXH, furnished a Form 6-K to the U.S. Securities and Exchange Commission on September 29, 2026 announcing that Liam Kelly will become its Chief Executive Officer effective October 1, 2026. Mr. Kelly will succeed Olivier Taelman. The 6-K attaches a press release titled "Nyxoah Appoints Liam Kelly as Chief Executive Officer," which is dated September 28, 2026.

The Appointment and Company Statements

The press release describes Mr. Kelly as a medical technology executive with more than 25 years of leadership experience. It says he served as Chairman, President and Chief Executive Officer of Teleflex (NYSE:TFX), until January 2026. He held the chief executive role from January 2018 and the chairman role from May 2020, and he joined Teleflex in 2009. During that time, according to the release, he progressed through senior positions that included Chief Operating Officer and president of several regional divisions. Before Teleflex, the release says, he spent a decade in senior management at Hill-Rom Holdings.

The release also states that Mr. Kelly currently serves as a director of Enovis Corporation (NYSE:ENOV), and that he holds a Bachelor of Business Studies from the University of Limerick.

Robert Taub, Chairman of Nyxoah, is quoted as saying: "Nyxoah is entering a new chapter, with the United States at the center of our growth strategy. We are very pleased to welcome Liam as our new CEO."

Mr. Kelly is quoted as saying: "I am incredibly excited to join Nyxoah at this pivotal stage. Genio is a truly differentiated technology in the treatment of sleep apnea."

About Nyxoah and Genio

The release describes Nyxoah as a company developing treatments for obstructive sleep apnea. Its lead product is the Genio system, which the release characterizes as a patient-centered, leadless, battery-free hypoglossal neurostimulation therapy. According to the release, Genio received the European CE Mark in 2019 and approval from the U.S. Food and Drug Administration in August 2025. The company says the therapy treats patients with Complete Concentric Collapse, a group it describes as contraindicated in competitor therapies. Those product characterizations are the company's own statements in the release and are not independent findings.

What the Release Does Not Say

The announcement does not say what role, if any, Mr. Taelman will have after Mr. Kelly takes over, and it does not say whether he will remain on the board. It does not give reasons for the change in leadership, and it does not disclose the terms of Mr. Kelly's compensation, any equity awards or any severance arrangements. As a foreign private issuer, Nyxoah reports on Form 6-K, which does not carry the itemized disclosure structure of a U.S. domestic company's Form 8-K, so details that an 8-K would require under its officer-change item may not appear in this filing.

Kelly Takes Over Nyxoah on October 1

Mr. Kelly's appointment takes effect on October 1, 2026, two days after the 6-K was furnished. Chairman Robert Taub says in the release that the United States is at the center of the company's growth strategy.